Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Staphylococcus aureus Protoheme IX farnesyltransferase (ctaB), partial CSB-YP743277SKW
CSB-EP743277SKW
CSB-BP743277SKW
CSB-MP743277SKW
CSB-EP743277SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Spermidine/putrescine import ATP-binding protein PotA (potA) CSB-YP743278SKW
CSB-EP743278SKW
CSB-BP743278SKW
CSB-MP743278SKW
CSB-EP743278SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus UPF0356 protein SAS1025 (SAS1025) CSB-YP743279SKW
CSB-EP743279SKW
CSB-BP743279SKW
CSB-MP743279SKW
CSB-EP743279SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Phosphoribosylformylglycinamidine cyclo-ligase (purM) CSB-YP743280SKW
CSB-EP743280SKW
CSB-BP743280SKW
CSB-MP743280SKW
CSB-EP743280SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Protein fmtA (fmtA) CSB-YP743281SKW
CSB-EP743281SKW
CSB-BP743281SKW
CSB-MP743281SKW
CSB-EP743281SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Probable glycolipid permease ltaA (ltaA), partial CSB-YP743282SKW
CSB-EP743282SKW
CSB-BP743282SKW
CSB-MP743282SKW
CSB-EP743282SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus ATP-dependent helicase/nuclease subunit A (addA), partial CSB-YP743283SKW
CSB-EP743283SKW
CSB-BP743283SKW
CSB-MP743283SKW
CSB-EP743283SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Na (+)/H (+) antiporter subunit C1 (mnhC1), partial CSB-YP743284SKW1
CSB-EP743284SKW1
CSB-BP743284SKW1
CSB-MP743284SKW1
CSB-EP743284SKW1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus UPF0349 protein SAS0809 (SAS0809) CSB-YP743285SKW
CSB-EP743285SKW
CSB-BP743285SKW
CSB-MP743285SKW
CSB-EP743285SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Extracellular matrix protein-binding protein emp (emp) CSB-YP743286SKW
CSB-EP743286SKW
CSB-BP743286SKW
CSB-MP743286SKW
CSB-EP743286SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Triosephosphate isomerase (tpiA) CSB-YP743287SKW
CSB-EP743287SKW
CSB-BP743287SKW
CSB-MP743287SKW
CSB-EP743287SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Prolipoprotein diacylglyceryl transferase (lgt), partial CSB-YP743288SKW1
CSB-EP743288SKW1
CSB-BP743288SKW1
CSB-MP743288SKW1
CSB-EP743288SKW1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus DegV domain-containing protein SAS0714 (SAS0714) CSB-YP743289SKW
CSB-EP743289SKW
CSB-BP743289SKW
CSB-MP743289SKW
CSB-EP743289SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Histidinol-phosphate aminotransferase (hisC) CSB-YP743290SKW
CSB-EP743290SKW
CSB-BP743290SKW
CSB-MP743290SKW
CSB-EP743290SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Putative glycosyltransferase tagX (tagX) CSB-YP743291SKW
CSB-EP743291SKW
CSB-BP743291SKW
CSB-MP743291SKW
CSB-EP743291SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Putative antiporter subunit mnhD2 (mnhD2), partial CSB-YP743292SKW
CSB-EP743292SKW
CSB-BP743292SKW
CSB-MP743292SKW
CSB-EP743292SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus GTP cyclohydrolase folE2 (folE2) CSB-YP743293SKW
CSB-EP743293SKW
CSB-BP743293SKW
CSB-MP743293SKW
CSB-EP743293SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus 30S ribosomal protein S7 (rpsG) CSB-YP743294SKW
CSB-EP743294SKW
CSB-BP743294SKW
CSB-MP743294SKW
CSB-EP743294SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus DNA-directed RNA polymerase subunit beta (rpoB), partial CSB-YP743295SKW
CSB-EP743295SKW
CSB-BP743295SKW
CSB-MP743295SKW
CSB-EP743295SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Staphylococcus aureus Serine acetyltransferase (cysE) CSB-YP743296SKW
CSB-EP743296SKW
CSB-BP743296SKW
CSB-MP743296SKW
CSB-EP743296SKW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>